Nonantioxidant Tetramethoxystilbene Abrogates α-Synuclein-Induced Yeast Cell Death but Not That Triggered by the Bax or βa4 Peptide by Derf, Asma et al.
Nonantioxidant Tetramethoxystilbene Abrogates α‑Synuclein-
Induced Yeast Cell Death but Not That Triggered by the Bax or βA4
Peptide
Asma Derf,†,‡ Ramesh Mudududdla,§,∥,⊥ Damilare Akintade,† Ibidapo S. Williams,†,# Mohd Abdullaha,§,∥
Bhabatosh Chaudhuri,*,†,‡ and Sandip B. Bharate*,§,∥
†Leicester School of Pharmacy, De Montfort University, Leicester LE1 7RH, U.K.
‡CYP Design Ltd, Innovation Centre, 49 Oxford Street, Leicester LE1 5XY, U.K.
§Medicinal Chemistry Division, Indian Institute of Integrative Medicine (CSIR), Canal Road, Jammu 180001, India
∥Academy of Scientific & Innovative Research, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India
*S Supporting Information
ABSTRACT: The overexpression of α-synuclein (α-syn) and its aggregation is the
hallmark of Parkinson’s disease. The α-syn aggregation results in the formation of
Lewy bodies that causes neuronal cell death. Therefore, the small molecules that can
protect neuronal cells from α-syn toxicity or inhibit the aggregation of α-syn could
emerge as anti-Parkinson agents. Herein, a library of methoxy-stilbenes was screened
for their ability to restore the cell growth from α-syn toxicity, using a yeast strain that
stably expresses two copies of a chromosomally integrated human α-syn gene.
Tetramethoxy-stilbene 4s, a nonantioxidant, was the most capable of restoring cell
growth. It also rescues the more toxic cells that bear three copies of wild-type or
A53T-mutant α-syn, from cell growth block. Its EC50 values for growth restoration of
the 2-copy wild-type and the 3-copy mutant α-syn strains are 0.95 and 0.35 μM,
respectively. Stilbene 4s mitigates mitochondrial membrane potential loss, negates
ROS production, and prevents nuclear DNA-fragmentation, all hallmarks of
apoptosis. However, 4s does not rescue cells from the death-inducing effects of
Bax and βA4, which suggest that 4s specifically inhibits α-syn-mediated toxicity in the yeast. Our results signify that
simultaneous use of multiple yeast-cell-based screens can facilitate revelation of compounds that may have the potential for
further investigation as anti-Parkinson’s agents.
1. INTRODUCTION
Parkinson’s disease (PD) is caused by the loss of neuronal cells
in the brain which leads to a reduction in dopamine that plays
a vital role in regulating the body movement. The
manifestations of PD include bradykinesia (slow movement),
postural instability, muscular rigidity, and resting tremors. The
overexpression of α-synuclein (α-syn) and βA4 proteins causes
accumulation of aggregated or mis-folded proteins which are
thought to be the key to the pathogenesis of PD and
Alzheimer’s disease. Aggregation results in the formation of
insoluble α-syn and βA4 deposits, referred to as Lewy bodies
that lead to neuronal cell death (i.e., neuronal apoptosis).1
Gene duplication, multiplication of the α-syn gene locus,2 and
point mutations in the α-syn gene that incorporate single
amino acid changes, such as Ala53Thr (A53T), lead to
overexpression of the 140-amino acid α-syn protein.3
Proteolytic cleavage of the precursor amyloid precursor protein
releases the 42-amino acid βA4 peptide which is overproduced,
mainly because of genetic reasons, in individuals suffering from
Alzheimer’s disease.4 The expression of human α-syn in the
baker’s yeast, Saccharomyces cerevisiae, results in the accumu-
lation of ROS followed by the manifestation of apoptosis.5 S.
cerevisiae has also been used to target a green fluorescent
protein (GFP)-tagged βA4 peptide to yeast’s secretory
pathway, with the help of a signal sequence upstream of the
βA4-GFP fusion gene. The secreted βA4 fusion protein
manifests toxicity in yeast.6 A number of studies have now
confirmed that yeast is a suitable system for studying the
pathogenesis of both human α-syn and βA4.5,7
Bax is a proapoptotic protein that belongs to the Bcl-2
family.8 It manifests its apoptotic function when bound to
mitochondrial membranes.9 It is very likely that Bax has a
much broader role than α-syn in neuronal cell death and plays
a major part in the overall regulation of neurodegenerative
processes that lead to neuronal apoptosis.10 More specifically,
in a mouse model of PD, Bax takes part in the destruction of
neurons that produce dopamine. Hence, it has been suggested
that down-regulation of Bax can be an attractive and novel
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therapeutic target for restricting the progression of PD.11 In
the yeast S. cerevisiae, the expression of Bax also generates ROS
which precedes apoptosis that is prevented by the anti-
apoptotic proteins of the Bcl-2 family, Bcl-2, and Bcl-xL.12 This
is similar to what has been observed in mammalian cells.13
We have cloned the gene coding for the human proteins α-
syn, its more toxic A53T mutant, Bax and βA4, under the
control of the galactose-inducible GAL1 promoter, in plasmids
that allow integration of gene expression cassettes at
chromosomal locations of a yeast strain (i.e., W303-1a;
ATCC 208352), via homologous recombination.14 The
human α-syn and the mutant A53T α-syn were cloned in
such a way that one to three copies of the gene could stably be
expressed from yeast chromosomes. For human βA4, yeast
strains were constructed that allow secretion of the peptide
from one copy or two copies of the gene. We have observed
that, with the increase of gene dosage or copy number (i.e.,
from one copy to two or three copies), the toxicity manifested
by α-syn and βA4 also increases. The human Bax protein was
expressed only from a single chromosomally integrated gene
where it showed enough toxicity to stop cell growth and
induce cell death. The two-copy wild-type α-syn expressing
yeast strain was used for the initial screening of a chemical
library of methoxy-stilbenes, to identify compounds which can
overcome the α-syn protein toxicity.
Because deposition of α-syn as neuronal inclusions,
synonymous to Lewy bodies, is likely to be the causative
agent of the disease suffered by most PD patients,15 targeting
toxicity manifested by α-syn overexpression is considered an
important approach for discovering new anti-PD drugs.16
Reported inhibitors of α-syn aggregation include N-methylated
derivatives of peptides from the α-syn protein sequence,17
single-chain antibodies,18 small-molecule antioxidant com-
pounds such as curcumin,19 epigallocatechin gallate
(EGCG),20 and 8-hydroxyquinolines.21 A large number of
naturally occurring polyphenolic compounds also have been
reported to inhibit the aggregation of α-syn and prevent its
toxicity.22 Among these polyphenols, the antioxidant stil-
benes23 viz. resveratrol (1), piceatannol (2), and 2,3,5,4′-
tetrahydroxystilbene-2-O-β-D-glucoside (TSG, 3) have been
shown to inhibit α-syn aggregation, although it has never been
shown that these compounds can overcome α-syn’s toxicity in
yeast, perhaps because of their relatively low permeability
across the yeast cell wall. Guo et al.24 have reported that
resveratrol ameliorates motor deficits and pathological changes
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice
via activation of SIRT1 and subsequent LC3 deacetylation-
mediated autophagic degradation of α-syn. Another phenolic
stilbene, piceatannol, a constituent of vine, inhibits the
formation of α-syn fibrils by destabilizing preformed
filaments.25 The glycosylated stilbene (TSG, 3, Figure 1A),
extracted from Polygonum multiflorum, inhibits α-syn aggrega-
tion and apoptosis in A53T mutant α-syn-transfected cells.26
In the present paper, the in silico-designed series of
methoxy-stilbenes were synthesized and studied for their
ability to protect yeast cells from α-syn mediated toxicity. The
tetramethoxy stilbene 4s (IIIM-959) was identified as the
unique compound, which is a nonantioxidant, and rescues the
more toxic cells that bear 3-copies of wild-type or A53T-
mutant α-syn, from cell growth block. However, it does not
rescue cells from the death-inducing effects of Bax and βA4.
The effect of 4s on inhibition of α-syn aggregation was also
studied. The results are presented in this paper.
Figure 1. (A) Structures of naturally occurring stilbenes 1−3 which inhibit α-syn aggregation. (B) Synthesis of methoxy-stilbenes 4a−4ac.
Reagents and conditions: (a) POCl3, dimethylformamide, room temp., 70−80%; (b) 7 (1 mmol), 6 (1 mmol), KOtBu (1 equiv), dry THF, 80 °C,
30 min, 60−95%.
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2. RESULTS AND DISCUSSION
2.1. Design and Synthesis of Methoxy-Stilbenes. The
structure of the α-syn monomer27 and its fibrils28 has been
studied by several groups. Preclinical studies have shown that
the α-syn fibrils cause Parkinson-like neurodegeneration in
nontransgenic mice models.29 Furthermore, recently Mach and
co-workers30 have shown that small molecules binds to various
pockets of the β-sheet structure (residue K34 to K97) of α-syn
fibrils which is rich in hydrophobic residues; thus it was
speculated that methoxystilbenes would display strong
interactions with the β-sheet structure. Thus, a series of
mono-, di-, tri-, and tetramethoxy-stilbenes were synthesized as
depicted in Figure 1B. The synthesis involved Wittig reaction
of aryl aldehydes 6 with phosphine salts 7 in the presence of
potassium tert-butoxide under anhydrous conditions. The
aldehydes which are not commercially available were
synthesized by Vilsmeier−Haack reaction. Using the synthetic
scheme as shown in Figure 1B, the stilbenes 4a−4ac were
obtained in excellent yields. A total of 29 stilbenes were
prepared and were characterized by NMR and MS analysis.
2.2. Construction of Yeast Strains That Contain One
Copy, Two Copies, and Three Copies of the Human α-
Syn Gene. At first, the plasmids were constructed that allow
the expression of 1-copy and 2- and 3-copies of the α-syn gene
in the yeast. A BglII-XbaI fragment of the coding sequence of
the human α-syn gene [NCBI Accession # NM_000345.3],
containing a 3′-end DNA sequence that codes for the HA-tag
peptide (consisting of the nine amino acid residues
YPYDVPDYA),31 was isolated from a human hippocampal
cDNA library (BioCat) by PCR and was cloned in yeast
integration vectors downstream of the GAL1 promoter [
Saccharomyces Genome Database ID S000000224] and
upstream of the SUC2 gene terminator signal [Saccharomyces
Genome Database ID S000001424]. The GAL1 promoter is
repressed in the presence of glucose and induced in the
presence of the sugar and galactose. After cloning of the HA-
tagged wild-type α-syn gene in appropriate yeast integrative
vectors, the following plasmids were obtained: YIpTRP1-
Gal1p/α-syn-HA, YIpHIS3Gal1p/α-syn-HA, and YIpURA3-
Gal1p/α-syn-HA (Figure 2). These plasmids contain the α-syn
gene sandwiched between the GAL1 promoter and the SUC2
terminator signal and allow integration of one copy, two
copies, and three copies of the α-syn gene into chromosomal
locations where the auxotrophic markers, TRP1, HIS3, and
URA3 genes, reside on the yeast genome.
The basic yeast strain used for integration was W303-1a
(Mata, ade2, his3, leu2, trp1, ura3) (ATCC #208352). Herein,
it is referred to as BC300. The yeast strain obtained after
integration of the plasmid YIpTRP1Gal1p/α-syn-HA in
BC300 was named BC300::α-syn-HA(TRP1); it contained a
single copy of the α-syn gene integrated at the TRP1
chromosomal locus. The plasmid YIpHIS3Gal1p/α-syn-HA
was integrated into the strain BC300::α-syn-HA(TRP1) to
obtain the strain BC300::α-syn-HA(TRP1), α-syn-HA(HIS3);
it contained two copies of the α-syn gene integrated at the
TRP1 and HIS3 chromosomal loci. The plasmid YIpUR-
A3Gal1p/α-syn-HA was integrated into the strain BC300::α-
syn-HA(TRP1), α-syn-HA(HIS3) to obtain the strain
Figure 2. Three integrative plasmids used to introduce HA-tagged human α-syn gene expression cassettes, under the control of the GAL1
promoter, into three different chromosomal locations (i.e., where the TRP1, HIS3, and URA3 genes lie) of the yeast genome. The arrows show the
restriction sites at which the plasmids were linearized for genomic (i.e., chromosomal) integration via homologous recombination.14
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BC300::α-syn-HA(TRP1), α-syn-HA(HIS3), α-syn-HA-
(URA3); it contained three copies of the α-syn gene integrated
at the TRP1, HIS3 and URA3 chromosomal loci. To generate
negative controls, the strain BC300 was integrated with empty
vectors (i.e., basic integrating vectors which do not contain the
α-syn gene) in three successive steps to obtain the three
strains: (a) BC300::(TRP1); (b) BC300::(TRP1),
(HIS3); and (c) BC300::(TRP1), (HIS3),
(URA3); they contain one copy, two copies, and three
copies of an empty plasmid at the (i) TRP1, (ii) TRP1&HIS3,
and (iii) TRP1, HIS3&URA3 chromosomal loci, respectively.
2.3. Growth of Yeast Strains That Contain (a) Two
and Three Copies of the Human α-Syn Gene and (b)
Two and Three Copies of Empty Plasmids, on Sold Agar
Minimal Medium Plates, Containing Glucose or Gal-
actose. Four clones from each of the three strains BC300::α-
syn-HA(TRP1), BC300::α-syn-HA(TRP1), α-syn-HA(HIS3),
and BC300::α-syn-HA(TRP1), α-syn-HA(HIS3), α-syn-HA-
(URA3), containing 1-copy, 2-copies, and 3-copies of the
human α-syn gene, respectively, were streaked out on solid
agar synthetic minimal medium plates that contained either
galactose (SG) or glucose (SD) as the carbon source. Cells
were grown at 30 °C for 96 h. In galactose-containing medium,
Figure 3. Growth of yeast strains containing two and three copies of the human α-syn gene, and analysis of cell death, MMP loss, ROS activity, and
nuclear DNA fragmentation. (A−F) Growth of yeast cells harboring one copy, two copies, and three copies of the human α-syn gene on minimal
medium solid agar plates that contained either glucose (SD) or galactose (SG). Panels (A−F), upper half (4 clones): strains containing one copy of
the α-syn gene or two and three copies of the α-syn gene. Panels (A−F), lower half (4 clones): strains containing an empty plasmid or empty
plasmids, without any α-syn gene, under the control of the GAL1 promoter. The solid agar plates were incubated at 30 °C for 96 h. (G) Western
blot analyses of cells expressing one to three copies of HA-tagged α-syn protein. On lanes 1, 2, and 3 were loaded total protein (10 μg) obtained
after lysis of cells that express one copy, two copies, and three copies of α-syn. The upper panel was probed with an antibody that recognizes the
HA epitope (Proteintech, 51064-2-AP) and the lower panel with a β-actin antibody (Proteintech, 60008-1-Ig); levels of β-actin were used as a
loading control, β-actin being a housekeeping gene. (H) Growth of yeast strains that contain one copy, two copies, and three copies of the α-syn
gene in liquid minimal medium yeast cell culture that contained galactose as a carbon source. OD600 represents the optical density of cells at 600
nm. The OD600 values at each time point represent the average of three independent experiments. (I) Analysis of cell deathpercentage of yeast
cells undergoing death after culturing strains expressing one copy, two copies, and three copies of α-syn for 20 h in galactose. Cells were stained
with Phloxine B for detection of dead cells.33 The data represent mean ± SD of five independent fields of observation. Around 200 cells were
counted in each field; (J) comparing the MMP of cells expressing one copy, two copies, and three copies of α-syn with cells containing empty
plasmids as controls. Cells were stained with the JC-10 dye to detect MMP loss.34 The data represent mean ± SD of three independent
experiments. (K) Total ROS activity of yeast strains containing one copy, two copies, and three copies of α-syn compared with strains than contain
empty plasmids. Cells were stained with dihydroethdium to detect ROS.35b The data represent mean ± SD of three independent experiments. (L)
Comparative levels of nuclear DNA fragmentation in yeast strains which express one copy, two copies, and three copies of α-syn, using the terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, compared with strains that contain empty plasmids.35b The data represent
mean ± SD of three independent experiments. For all four sets of analyses (I−L), cells were cultured for 20 h in galactose, for induction of α-syn
protein expression, before treatment of cells, as required by the assay [statistical analysis was performed in (I−L) for comparison between the 1C,
2C, and 3C α-syn with the respective control group, ***p < 0.01].
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the α-syn gene is induced by the GAL1 promoter and, hence,
the protein must be produced, whereas in glucose, the α-syn
protein should not be produced because the gene expression is
repressed. The strains (a) BC300::(TRP1),(b)
BC300::(TRP1), (HIS3), and (c) BC300::(TRP1),
(HIS3), (URA3) [containing one copy, two copies, and
three copies of empty plasmids that do not contain the α-syn
gene] were used as negative controls. The results show that
expression of 1-copy, 2-copies, and 3-copies of the α-syn gene
from different chromosomal loci block the growth of cells in
galactose, but not in glucose. Control strains containing 1-
copy, 2-copies, and 3-copies of empty plasmids grow, as
expected, both in SG and SD media (Figure 3A−F). It was
inferred that the human α-syn protein must be toxic to the
yeast, as has been reported earlier.32 Cells were grown in
minimal SG liquid medium containing galactose. Total cellular
proteins were obtained via lysis of cells, and they were
examined for the expression of the human α-syn protein.
Western blot results show that the levels of α-syn protein,
expressed in the yeast increase as the copy number increases
Table 1. Rescue from the Block in the Growth of Yeast Cells That Express Two Copies of α-Syn, by Methoxy-Stilbenes, at 10
μM Concentration
aThe data represent mean ± SD of four independent experiments.
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from 1 to 3 (Figure 3G). This would suggest that
manifestation of α-syn protein’s toxicity (i.e., block in cell
growth) would increase with the increasing copy number from
1-copy to 2- and 3-copies of the α-syn gene.
Cell growth of the strains (a) BC300::α-syn(TRP1), (b)
BC300::α-syn(TRP1), α-syn(HIS3), and (c) BC300::α-syn-
(TRP1), α-syn(HIS3), α-syn(URA3) containing one copy,
two copies, and three copies of the human α-syn gene, was
compared in minimal liquid SG medium containing galactose
(Figure 3H). The graphs show that the strains containing 1-
copy, 2-copies, and 3-copies of the human α-syn gene do not
grow in SG liquid medium, whereas the strains containing the
empty plasmids do grow in the same medium. The strains were
grown at 30 °C over a period of 48 h in liquid culture. The
results again indicate that the human α-syn gene, when
expressed in a galactose-containing yeast cell culture medium,
completely blocks cell growth. The strain BC300::α-syn-
(TRP1), containing a single copy of the α-syn gene, was not
used any further in these studies. Although the expression of a
single copy also blocked cell growth on agar plates, it was clear
from Figure 3G that the BC300::α-syn(TRP1) expressed the
least amount of α-syn protein.
To identify compounds in a screen of a library of methoxy-
stilbenes, we wished to identify a compound that would
overcome the maximum levels of toxicity mediated by α-syn, in
yeast cells. Hence, it was thought that yeast strains which
express 2-copies and 3-copies of the α-syn gene may be more
appropriate for screening of chemical libraries to see if
compounds could be identified that would overcome cell
growth. Before embarking on such a screen, it was necessary to
clarify the levels of cell death that the newly constructed yeast
strains undergo, upon the expression of human α-syn. Cells,
after the expression of α-syn in galactose, were treated with the
dye Phloxine B which stains dead cells red.33 The percentage
of cell death, in the one- to three-copy α-syn expressing strains
and the corresponding empty strains (i.e., cells which do not
harbor the α-syn gene), is shown in Figure 3I. Increasing cell
death was observed with the increasing α-syn copy number.
Next, the loss of mitochondrial membrane potential (MMP) in
yeast cells expressing one copy, two copies, and three copies of
human α-syn was assessed. It has been suggested that α-syn
aggregation causes mitochondrial dysfunction and thereby
affects MMP34 which allows release of ROS35 that leads to
neuronal apoptosis, a form of programmed cell death. It was,
therefore, necessary to find out if these newly constructed α-
syn-expressing yeast strains suffer from loss of MMP, generate
ROS, and undergo apoptosis. Yeast strains expressing one
copy, two copies, and three copies of α-syn do show gradual
loss of MMP with the increasing copy number (Figure 3J).
Concomitantly, yeast strains expressing one copy, two copies,
and three copies of α-syn generate increasing levels of ROS
with the copy number increase (Figure 3K). It was also seen
that the three-copy α-syn-bearing cells undergo the most
nuclear DNA fragmentation which mirrors the degree of
apoptosis, that is, the two-copy and one-copy strains suffer less
apoptosis than the three-copy strain (Figure 3L).35
2.4. Screening of the Methoxy-Stilbene Library in the
Two-Copy Wild-Type α-Syn Strain. The 29-compound
Figure 4. (A−F), Growth of yeast cells harboring one copy, two copies, and three copies of the human α-syn (A53T) gene, on minimal medium
solid agar plates that contained either glucose (SD) or galactose (SG). Panels (A−F), upper half (4 clones): strains containing one copy, two
copies, or three copies of the α-syn(A53T) gene, under the control of the GAL1 promoter that induces the expression of α-syn(A53T) protein, in
the presence of galactose. Panels (A−F), lower half (4 clones): strains containing an empty plasmid or empty plasmids, without any α-syn (A53T)
gene. The solid agar plates were incubated at 30 °C for 96 h. (G) Growth of yeast strains that contain one copy, two copies, or three copies of the
α-syn (A53T) mutant gene and empty plasmids (1 to 3-copies) in liquid yeast cell culture minimal medium that contained galactose. The OD600
values at each time point represent the average of three independent experiments. (H) Percentage of cells undergoing death in yeast strains
expressing one copy, two copies, and three copies of α-syn (A53T), after cells were cultured for 20 h in SG medium. Dead cells were stained with
Phloxine B. The data represent mean ± SD of five independent fields of observation (statistical significance, ***p < 0.01). Around 200 cells were
counted in each field. (I) Rescue from the block in growth of yeast cells that express (a) three copies of wild-type α-syn(wt) [3C-α-syn(wt)] and
(b) three copies of mutant α-syn(A53T) [3C-α-syn(A53T)], by methoxy-stilbenes, at 10 μM concentration. This is compared with the growth that
had been seen in the two-copy wild-type α-syn strain. The data represent mean ± SD of four independent experiments.
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chemically synthesized methoxy-stilbene library was screened
using a yeast strain that expresses two copies of HA-tagged
human α-syn from chromosomal loci. Compounds, at 10 μM
concentration in 5% dimethyl sulfoxide (DMSO), were
incubated at 30 °C with two-copy α-syn-expressing cells in
minimal SG medium (that contained 2% galactose and 0.2%
glucose) in 96-well microtiter plates. The plates were shaken at
200 rpm for 72 h. The growth of cells (measured by
monitoring the optical density of cells at 600 nm; OD600), in
the absence of compounds but in the presence of 5% DMSO,
was used as the base for calculating the percentage growth in
the presence of compounds. The results are shown in Table 1.
We have used another chemical library consisting of 20
“quinazolinones”36 to show that one does not obtain “hits” in
this yeast-based α-syn screen from any chemical library. One
may refer to this as a negative control for such a screen. Results
are shown in the Supporting Information, Section S1. The five
best compounds 4f, 4q, 4r, 4s, and 4u that rescue growth of
the two-copy α-syn expressing yeast cells, in liquid culture, also
rescue growth of the same cells on solid agar plates
(Supporting Information, Section S2).
2.5. Yeast Cells Expressing One to Three Copies of
the A53T α-Syn Mutant Protein Block Cell Growth and
Induce Cell Death. The hits identified in the yeast strain that
expresses two copies of α-syn were further tested for their cell
rescuing ability in strains that express three copies of wild type
α-syn, and also three copies of mutant α-syn (A53T); the
plasmids encoding the A53T mutant α-syn gene are shown in
Section S3 of the Supporting Information. The A53T amino
acid change in the primary protein sequence of α-syn is the
result of a familial mutation in the α-syn DNA sequence that is
linked to PD.37 It has been claimed that it is the most
amyloidogenic α-syn mutant protein, implying that it is also
more prone to aggregation than the other known α-syn
mutants. Hence, it has been predicted to be the most toxic
among all α-syn protein variants. Similar to the wild type α-syn
protein, the expression of the A53T mutant blocks yeast cell
growth in solid agar and liquid culture media that contain
galactose (Figure 4A−G). Again, similar to wild type α-syn,
expression of one to three copies of the A53T α-syn mutant
induces cell death after the growth of cells, for 20 h, in liquid
culture medium containing galactose (Figure 4H). Cell death
increases with the copy number.
All 29 compounds in the methoxy-stilbene library were
separately tested, at 10 μM concentration, in the strains that
express (a) three copies of wild-type α-syn(wt) [i.e., 3C-α-
syn(wt)] and (b) three copies of mutant α-syn(A53T) [i.e.,
3C-α-syn(A53T)]. Cells were incubated, at 30 °C, in the
presence or absence of compounds, in 96-well plates in SG
medium (that contained 2% galactose and 0.2% glucose); the
plates were shaken at 200 rpm. It was observed that the
compounds, which had been identified in the screen using the
two-copy wild-type α-syn strain, also restore cell growth in
these two new strains, in the presence of 2% galactose and
0.2% glucose (Figure 4I). Percentage growth was again
calculated based on the growth of the respective cells in
galactose (SG medium) and in the presence of only 5%
DMSO, but no compound, which was considered as zero
percent or base line. It should be noted that the cells
expressing three copies of α-syn and three copies of the mutant
A53T α-syn hardly grew in SG, over 72 h, compared to the
strain that expresses two copies of α-syn which had been used
for the initial screen. This may be one of the reasons why the
calculated percentage growth appears to be relatively higher,
for some of the compounds, in the three-copy wild-type α-syn
and mutant α-syn strains than the strain bearing two-copy
wild-type α-syn. The two compounds, 4f and 4s, proved to be
the best in rescuing growth of three-copy α-syn expressing
yeast cells, in liquid culture (Figure 4I). They also rescued
growth of the same cells on solid agar plates (Supporting
Information, Section S4).
2.6. Determination of EC50 Values of Selected
Methoxy-Stilbenes That Restore Growth in α-Syn-
Expressing Yeast Cells. We have determined the EC50
values of the five compounds which restored growth the
best, in liquid culture and on solid agar, in cells blocked in
growth by expression of two copies of wild-type α-syn. For
determination of EC50 values, cells were grown for 48 h at 30
°C, in the presence of different concentrations of compounds
in wells of 6-well plates. The OD600 values were plotted against
compound concentrations to calculate the EC50 values. Results
are shown in Table 2. The EC50 value for compound 4s, in the
strain expressing three copies of A53T mutant α-syn, which has
been found to be the most toxic among α-syn variants,38 was
determined to be 0.35 μM.
2.7. Methoxy-Stilbenes 4q, 4r, and 4s Prevent Cell
Death and Restore Life in Cells Expressing α-Syn. The
three best compounds, 4q, 4r, and 4s, identified in the initial
screen of the methoxy-stilbene library using the two-copy wild-
type α-syn-bearing yeast strain, were then tested for their
Table 2. EC50 Values of the Five Best Methoxy-Stilbenes in Their Ability to Rescue Growth of Cells That Express Two Copies
of Wild-Type α-Syn
aThe determined EC50 values represent mean ± SD of three independent experiments.
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ability to prevent cell death and also restore life in yeast cells
which express three copies of α-syn; the reason for choosing
the three-copy strain was because it manifests more toxicity
than the two-copy cells (see Figure 5).
The results, obtained after treatment of three-copy cells with
the compounds, are shown in Figure 5. Death of yeast cells,
caused by the expression of human α-syn, was visualized by
staining with the dye, Phloxine B. Dead cells are stained red.
The observations (in Figure 5A,B) indicate that, in the
presence of the three compounds, 4q, 4r, and 4s, there is a
remarkable decrease in cell death mediated by α-syn. In
parallel, we show that the compounds provide once again life
to the cells which are being inflicted by the toxic human α-syn
by staining cells with the Hoechst 33342 dye (Figure 5C,D).
The Hoechst dye is used for fluorescent staining of DNA and
nuclei of live cells, including that of the yeast.39
2.8. Apoptosis Induced by the Expression of Human
α-Syn in Yeast Is Prevented by Treatment with
Compounds 4q, 4r, and 4s. In eukaryotic cells, ROS
emanates from the mitochondrion, an intracellular compart-
ment responsible for respiration. Perpetual increase in the
production of ROS production, because of mitochondrial
dysfunction, leads to accumulation of ROS within cells which
is likely to result in damage of DNA, proteins, and lipids. This
ROS-perpetrated damage prevents proper functioning of the
cells. It has been demonstrated that the consequence of
mitochondrial dysfunction and increase in ROS levels,
depending on the degree of ROS production and the loss of
mitochondrial function, is the induction of apoptosis.40
Mitochondrial dysfunction usually implies opening up the
mitochondrial permeability transition pore (mtPTP) which
induces depolarization of the mitochondrial transmembrane
potential with attendant release of apoptogenic factors and loss
of mitochondria’s innate oxidative phosphorylation capacity.
The mtPTP has been recognized as a potential pharmaco-
logical target for the treatment of neurodegenerative diseases,
like PD, in which excessive cell death occurs because of
mitochondrial dysfunction.41
The cellular toxicity seen on the expression of human α-syn
in mammalian cells has precisely been reproduced in the
baker’s yeast, S. cerevisiae.42 Yeast cells, expressing human α-
syn, do undergo apoptosis because of oxidative stress
originating from generation of excess ROS, triggered by
misfolding of α-syn, and accompanied by mitochondrial
dysfunction.43 We show in Figure 6B that nuclear DNA
fragmentation in three-copy α-syn-bearing yeast cells is mostly
abrogated by compounds 4q, 4r, and 4s. We then investigated
if the compounds, 4q, 4r, and 4s, would also mitigate loss of
MMP and negate production of ROS. The compounds indeed
prevent MMP loss and increased levels of ROS formation
caused by expression of three copies of human α-syn in yeast
(Figure 6C,D).
Figure 5. Effect of three best compounds, 4q, 4r, and 4s, which restore cell growth in the two-copy α-syn screen, on α-syn-induced cell death. Cells,
harboring three copies of α-syn, were grown in SG minimal medium, containing galactose, for 20 h at 30 °C, before further treatment with Phloxine
B or Hoechst 3342 dye. (A) Cells grown in the absence or presence of compounds, 4q, 4r, and 4s stained with Phloxine B. (B) Percentage of dead
cells in the absence of any compound and in the presence of the three compounds, 4q, 4r, and 4s. The data represent mean ± SD of five
independent fields of observation (statistical significance, ***p < 0.01). Around 150 cells were counted in each field. (C) Cells stained with the
Hoechst 33342 dye. The upper two panels are the controls showing that most cells are alive in glucose-containing SD medium (because there is no
α-syn expression), whereas they are dead in SG medium that contains galactose. In the presence of compounds 4q, 4r, and 4s, cells grown in
galactose-containing SG medium are resistant to the toxic effects of α-syn. (D) Percentage of live cells, in SG medium, in the absence of any
compound and in the presence of the three compounds, 4q, 4r, and 4s. The data represent mean ± SD of five independent fields of observation
(statistical significance, ***p < 0.01). In (D), the statistical significance was determined by comparison of compound-treated live cells vs control
cells containing galactose.
ACS Omega Article
DOI: 10.1021/acsomega.8b01154
ACS Omega 2018, 3, 9513−9532
9520
2.9. Antioxidant Activity of Identified Hits in the 1,1-
Diphenyl-2-picrylhydrazyl (DPPH) and 2,2′-Azino-bis-3-
ethylbenzthiazoline-6-sulphonic Acid (ABTS) Assays.
The antioxidant potential of selected methoxy-stilbenes was
evaluated in two assays that allow determination of the
compounds’ ability to scavenge free radicals generated by (a)
DPPH44 and (b) ABTS45 (Figure 7). Among the compounds
identified as rescuers of human α-syn’s toxicity in the yeast,
only one compound, 4r, has some antioxidant activity when
compared with trolox, a vitamin E analogue. None of the other
methoxy-stilbenes seem to be antioxidants, although resvera-
trol and piceatannol (on the basis of which the methoxy-
stilbene library was synthesized) have been found to be strong
antioxidants using the same DPPH and ABTS assays.23 We
have confirmed that resveratrol is an antioxidant in both the
DPPH and ABTS assays and piceatannol is an antioxidant in
the ABTS assay (Section S5, Supporting Information).
2.10. Testing of Methoxy-Stilbenes for Rescue of
Human Bax-Expressing Yeast Cells. All 29 methoxy-
stilbenes were then tested in the yeast strain that expresses a
single copy of the human Bax gene with the aim of identifying
compounds that may overcome Bax-mediated block of cell
growth and to see if there were compounds that nullified the
toxicity of both α-syn and Bax. The synthetic Bax gene,
synthesized on the basis of the published protein sequence for
Bax-α (NCBI Accession # AAA03619), was cloned with a 3′-
end DNA that codes for the c-myc tag (peptide sequence,
EQKLISEEDL) in a yeast integrative plasmid (see Section S6,
Supporting Information). A chromosomally integrated copy of
the human Bax gene in the yeast strain BC300 (as described
before) was expressed under the control of the galactose-
inducible GAL1 promoter.12 Because the yeast cells that
express Bax do not grow in galactose, it would indicate that the
expression of the Bax protein (Figure 8C) is toxic to the yeast
(Figure 8A,B). The Bax expression also causes yeast cell death
(Figure 8D). Bax-expressing yeast cells were incubated in SG
medium, at 30 °C, in the presence or absence of compounds in
96-well plates; the plates were shaken at 200 rpm. The results
obtained in the screen of methoxy-stilbenes with Bax-
expressing yeast cells are summarized in Figure 8E.
Compound 4aa stands out because it rescues only Bax’s
toxicity in the yeast but not α-syn’s. It is possible that it
prevents cell death at a juncture, perhaps via a protein or a
protein, which is not shared by the biochemical pathways used
by Bax and α-syn to inflict death on yeast cells. On the other
hand, the compounds 4f, 4r, and 4s are unable to overcome
Bax-induced yeast cell death, triggered by mitochondrial
dysfunction,12 but still can rescue α-syn-mediated apoptosis
which, similar to the Bax expression in yeast, also occurs via
loss of MMP and generation of excess ROS. It is, therefore,
very likely that compounds 4f, 4r, and 4s are the ones that
prevent aggregation of α-syn and thereby prevent α-syn-
mediated apoptosis (for visualization of concept, see Figure 8).
Hence, we asked the question whether compounds 4f, 4r, and
4s would also prevent the aggregation of the βA4 peptide. We
have found that, like in human cells, overexpression of βA4
causes yeast cell death. It has earlier been shown that the
overexpression of a GFP-tagged βA4 in the yeast leads to its
Figure 6. Effect of the three best compounds, 4q, 4r, and 4s, which restore cell growth in the two-copy α-syn screen, on α-syn-induced nuclear
DNA fragmentation which occurs only in apoptotic cells. Cells, harboring three copies of α-syn, were grown in SG minimal medium, containing
galactose, for 20 h at 30 °C, before assessing for nuclear DNA fragmentation with the TUNEL assay. (A) Cells, grown in SG medium, in the
absence or presence of compounds, 4q, 4r, and 4s, which incorporate the fluorescence dye TF3 and modified deoxyuridine 5′-triphosphate (TF3-
dUTP) at the 3′-OH ends of apoptotic DNA fragments. The uppermost panel shows that there is hardly any DNA fragmentation in cells that do
not express α-syn, in the presence of glucose in contrast to cells which express α-syn, in the presence of galactose. The levels of DNA fragmentation
in cells grown in galactose, in the presence of compounds, are much less than in cells expressed in galactose, in the absence of compound. (B)
Comparison of the relative levels of nuclear DNA fragmentation in cells grown in galactose, in the presence of compounds, with cells grown in the
absence of compounds, in galactose. Labeled DNA of cells which do not express α-syn, in medium containing glucose, acted as a positive control.
DNA labeling is expressed as relative fluorescence units (statistical significance, * 0.05 > p < 0.1). (C) Effect of the three best compounds, 4q, 4r,
and 4s, on α-syn-induced loss of MMP (statistical significance, *p < 0.25). (D) Effect of the three best compounds, 4q, 4r, and 4s on α-syn-induced
increase of levels of ROS in the three-copy α-syn-expressing yeast cells (statistical significance, ***p < 0.01).
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spontaneous aggregation, thereby causing toxicity but not cell
death.6b,46
2.11. Testing of Methoxy-Stilbenes for Rescue of
Human βA4-Expressing Yeast Cells. The seven methoxy-
stilbenes depicted in Figure 8E were next tested in the yeast
strain that secretes two copies of the 42-amino acid human
βA4 peptide gene (i.e., in cells where the βA4 peptide is
targeted to yeast’s secretory pathway with the help of a signal
sequence), to see if any of these compounds overcome βA4-
mediated block in cell growth. It has been reported that, like in
human cells, βA4 is only toxic to yeast cells when it enters the
pathway that allows secretion of a protein/peptide from
eukaryotic cells.6 The synthetic human βA4 gene, with the 5′-
end invertase signal sequence (Invss),
47 was synthesized on the
basis of the published βA4 protein sequence (NCBI Accession
# P05067). The Invss-βA4 gene and the βA4 gene (without the
Invss) were cloned in two yeast integrative plasmids that allow
integration at the HIS3 and URA3 chromosomal loci (see
Section S7, Supporting Information). Chromosomally inte-
grated copies (i.e., 1-copy and 2-copies) of the Invss-βA4 gene
and the βA4 gene (without the Invss) were expressed, in the
yeast strain BC300, under the control of galactose-inducible
GAL1 promoter. Because the yeast cells that express secreted
βA4 do not grow in galactose (Figure 9I,II), which is in
contrast to cytosolic the expression of βA4 (i.e., without the
Invss), where cells do grow, it would indicate that the
expression of only the secreted βA4 peptide (Figure 9III) is
toxic to the yeast. Secretion of the βA4 peptide, but not its
cytosolic expression, causes yeast cell death (Figure 9IV).
The selected methoxy-stilbenes were tested to see if they
would overcome secreted human βA4-mediated cell death in
the yeast. Yeast cells, expressing two copies of Invss-βA4, were
incubated in 96-well plates, at 30 °C, in the presence or
absence of compounds; the plates were shaken at 200 rpm.
The results, depicted in Figure 10A, obtained using these cells,
Figure 7. Antioxidant activity of methoxy-stilbenes at 10 μM
concentration. The antioxidant capacity of the compounds is
compared with the standard Trolox, a soluble vitamin E equivalent
(also at 10 μM concentration). (A) Antioxidant potential in the
scavenging of the free radicals generated by DPPH. The “Control”
contained DPPH and 5% DMSO but no compound. (B) Antioxidant
potential in the scavenging of the free radicals generated by ABTS.
The antioxidant capacity of the compounds is again compared with
the standard Trolox. The “Control” contained ABTS and 5% DMSO
but no compound. The data in both (A,B) represent mean ± SD of
three independent experiments (statistical significance, ns, p > 0.25).
Figure 8. (A) Solid agar plates depicting the growth of yeast cells that express human Bax protein and cells that do not contain Bax, in minimal
medium containing either glucose (SD) or galactose (SG). (B) Growth of one set of clones from the strains, as in (A), in liquid minimal medium
containing galactose (SG); the OD600 values at each time point represent the average of three independent experiments (*P < 0.01; one-tailed
Student’s t-test). (C) Western blot of total cellular proteins obtained after lysis of cells that do not express Bax (BC300::) and do express c-myc-
tagged Bax (BC300::Bax), probed with a c-myc antibody (Thermo Scientific, MA 1-980), and a β-actin antibody (Proteintech, 60008-1-Ig) as a
loading control, β-actin being a housekeeping gene. (D) Staining of cells that express BC300:: and BC300::Bax, with Phloxine B, under the
fluorescent microscope. The left-hand panels show cells in phase contrast microscopy. (E) Rescue from the block in growth of yeast cells that
express human Bax, by methoxy-stilbenes, at 10 μM. The data represent mean ± SD of four independent experiments where optical density at 600
nm (OD600) was measured for each cell culture.
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were compared with those obtained from human Bax-
expressing yeast cells and the three different strains that
express human α-syn. None of the methoxy-stilbenes that had
restored cell growth suppressed by α-syn had any ability to
rescue cells that were blocked in growth by two copies of
secreted βA4. This was also confirmed by attempting to form
yeast colonies on solid agar plates, in the presence of
compounds 4f, 4q, 4r, 4s, and 4u (10, 5, and 2.5 μM
concentrations), from cells that express two copies of secreted
βA4 in SG minimal medium containing galactose (Section 8,
Supporting Information). EGCG was used as a positive control
in this set of experiments.20,48
The results, presented in Figure 10A, strongly suggest that
the compounds 4f, 4r, and 4s specifically target the aggregation
of α-syn, but surprisingly not that of βA4. These three
compounds are also unable to prevent Bax-mediated block in
cell growth and induction of cell death. It could be inferred
that, only by preventing α-syn aggregation, the compounds 4f,
4r, and 4s inhibit the toxic manifestations of the over-
expression of human α-syn in the yeast that result in loss of
MMP, ROS generation, and resultant apoptosis (Figure 10B).
2.12. Prevention of α-Syn Aggregation by Com-
pound 4s. The compound 4s was further tested in yeast cells
expressing two copies of α-syn-eGFP fusion protein. As shown
in the fluorescence picture of cells expressing two copies of α-
syn-eGFP fusion protein in the absence of compounds (Figure
11C), the cells marked with white arrows shows α-syn
aggregation, whereas the ones with yellow arrows show dead
cells. However, when the cells were treated with compound 4s
at 5 μM, cells do not show aggregation of α-syn (Figure 11D).
The results show that compound 4s is likely to have the ability
to prevent α-syn aggregation (Figure 11A−D).
3. CONCLUSIONS
The screening of a library of methoxy-stilbenes, in parallel,
using yeast cells that express human α-syn, Bax, and βA4, has
resulted in the identification of compound 4s as a likely
inhibitor of α-syn aggregation. The compound 4s does not
possess antioxidant properties. It prevents yeast cell death
brought about by expression of two copies and three copies of
the wild-type α-syn gene as well as three copies of its A53T
mutant. However, it does not rescue yeast cells from Bax- and
βA4-induced death. The in silico docking studies indicated that
it binds to the two sites on the β-sheet of the α-syn fibrils. The
results presented in this paper suggest that compound 4s could
be used for further exploration in preclinical studies related to
PD. Results also illustrate that simultaneous use of three sets of
recombinant yeast cells, which express human α-syn, Bax, and
βA4, could rapidly reveal compounds from a chemical library
that may specifically prevent the aggregation of α-syn.
4. EXPERIMENTAL SECTION
4.1. General. 1H, 13C, and DEPT and 2D-NMR spectra
were recorded on Brucker-AVANCE DPX FT-NMR 500 and
400 MHz instruments. NMR experiments were carried out in
the indicated solvent. Chemical data for protons are reported
in parts per million downfield from tetramethylsilane and are
referenced to the residual proton in the NMR solvent
Figure 9. (I) Growth of yeast cells harboring one copy and two copies of the human βA4 gene on minimal medium solid agar plates that contained
either glucose (SD) or galactose (SG). Panels (A−F), upper half (4 clones): strains containing one copy or two copies of the Invss-βA4 gene, under
the control of the GAL1 promoter that induces the expression of βA4 protein. Panels (A−D), lower half (4 clones): strains containing one copy
and two copies of the βA4 gene, without the invertase signal sequence (Invss). The solid agar plates were incubated at 30 °C for 96 h. (II) Growth
of yeast strains that contain one copy and two copies of the Invss-βA4 gene and the βA4 gene (without the Invss), in liquid yeast cell culture minimal
medium that contained galactose. The OD600 values at each time point represent the average of three independent experiments. (III) Western blot
of total cellular proteins obtained after lysis of cells that express cytosolic βA4 (lane 1), one copy of secreted Invss-βA4 (lane 2) and two copies of
Invss-βA4 (lane 3), probed with a βA4 antibody (Abcam, ab12267); the same proteins were probed with a β-actin antibody (Proteintech, 60008-1-
Ig), which acted as a loading control. (IV) Percentage of cells undergoing death in yeast strains expressing one copy (panels C,D) and two copies of
secreted Invss-βA4 (panels E,F), after cells were cultured for 20 h. Cells expressing two copies of cytosolic βA4, without the Invss signal sequence,
are represented in panels A and B. Dead cells were stained red with Phloxine B. The data represent mean ± SD of five independent fields of
observation. Around 200 cells were counted in each field. The left-hand panels show cells in phase contrast microscopy.
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(CD3OD 3.31 ppm). Carbon nuclear magnetic resonance
spectra (13C NMR) were recorded at 125 or 100 MHz:
chemical data for carbons are reported in parts per million (δ
scale) downfield from tetramethylsilane and are referenced to
the carbon resonance of the solvent (CD3OD, 49.0 ppm). ESI-
MS and HRMS spectra were recorded on Agilent 1100 LC-Q-
TOF and HRMS-6540-UHD machines. All chromatographic
purifications were performed on Sephadex and Dianion HP-20
resin. Thin layer chromatography was performed on precoated
silica gel 60 GF254 aluminium sheets (Merck). All solvents used
were of analytical grade and purchased from Merck. The
HPLC purity analysis of all samples was carried out on a
UPLC Shimadzu system (LC20ADXR), connected with a
Lichrosphere RP18e (5 μ, 4.6 mm × 250 mm) column, and
was eluted with water (0.1% formic acid): ACN gradient at the
flow rate of 0.8 mL/min. The gradient elution was set with the
increasing concentration of ACN in following format: 5% ACN
(0−3 min), 5−80% ACN (3−8 min), 80% ACN (8−12 min),
80−20% ACN (12−14 min), and 5% ACN (14−16 min). The
detection wavelength used was 254 nm. All compounds
comply the purity requirement of >95% (HPLC purity).
4.2. General Procedure for Preparation of (E/Z)-1-
Styryl Methoxybenzene 4a.
To the stirred solution of benzyl triphenylphosphine halide salt
7 (2.8 mmol) in anhydrous THF (10 mL) under N2
atmosphere was added potassium tert-butoxide (3.0 mmol)
in small portions at 0−5 °C, and the resulting mixture was
stirred at 80 °C for 30 min. Formation of orange color was
observed in the reaction. Reaction was cooled to the room
temperature, and the respective 2-methoxy benzaldehyde 6
(0.5 g, 2.5 mmol) was added. The resulting reaction mixture
was again refluxed at 80 °C for 30 min. The reaction mixture
was quenched with ethyl acetate (10 mL), and the solvent was
evaporated under vaccum, followed by partitioning between
water and ethyl acetate (50 mL × 2). The organic layer was
collected, dried on anhydrous sodium sulphate, and evaporated
on a rotary evaporator to get the crude product. The crude
product was purified by silica gel (#100-200) column
chromatography using 20% EtOAc/hexane to get (E/Z)-1-
styryl methoxybenzene 4a in 95% yield. The ratio of cis/trans
isomer in isolated products was determined by HPLC. All
other stilbenes 4b−4ac were synthesized using a similar
procedure.
4.2.1. (E/Z)-1-Styryl-2,4,6-trimethoxybenzene (4a). Mix-
ture of cis/trans isomers (43:56 ratio, determined based on
HPLC); Light yellow oil; 1H NMR (CDCl3, 400 MHz) of
trans-isomer: δ 7.51 (d, J = 7.6 Hz, 2H), 7.43 (d, J = 12.4 Hz,
1H), 7.33 (t, J = 7.6 Hz, 2H), 7.19 (m, 2H), 6.16 (s, 2H), 3.87
(s, 6H), 3.83 (s, 3H); 1H NMR (CDCl3, 400 MHz) of cis-
isomer: δ 7.48 (m, 1H), 7.43 (m, 1H), 7.36 (m, 1H), 7.19 (d, J
= 7.6 Hz, 1H), 7.12 (m, 1H), 6.67 (d, J = 12 Hz, 1H), 6.42 (d,
J = 12.4 Hz, 1H), 6.10 (s, 2H), 3.82 (s, 3H), 3.57 (s, 6H); 13C
NMR (CDCl3, 125 MHz): δ 160.8, 160.2, 159.5, 158.3, 139.6,
139.0, 131.1, 129.9, 128.4, 127.8, 127.6, 126.5, 126.1, 120.9,
119.8, 108.1, 90.7, 90.6, 55.8, 55.4, 55.3; IR (CHCl3) νmax:
3436, 3079, 3056, 3000, 2959, 2936, 2533, 2155, 2109, 1955,
1726, 1605, 1594, 1584, 1514, 1497, 1466, 1455, 1436, 1377,
1331, 1271, 1214, 1205, 1190, 1155, 1140, 1122, 1072, 1060,
1038 cm−1; ESI-MS m/z: 271.1 [M + H]+.49
Figure 10. (A) Summary of the methoxy-stilbenes effect on the growth of human α-syn, βA4, and Bax-bearing yeast cells at 10 μM. The two-copy
Invss-βA4 strain was used, in the presence of 10, 5, and 2.5 μM compounds, on SG agar plates. The data represent mean ± SD of four independent
experiments where optical density at 600 nm (OD600) was measured for each cell culture. (B) Cartoon depicts some of the possible pathways that
can lead to apoptosis, when the human proteins α-syn, βA4, and Bax are expressed in the yeast. It shows the points in the pathways that certain
methoxy-stilbenes can act and prevent apoptosis.
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4.2.2. (E)-1-(3′,4′-Dimethoxystyryl)-2,4,6-trimethoxyben-
zene (4b). Trans-isomer (93.7% determined based on
HPLC); white amorphous solid; mp 124−126 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.41 (d, J = 16.4 Hz, 1H), 7.25 (d, J =
16.4 Hz, 1H), 7.06 (d, J = 13.6 Hz, 2H), 6.84 (d, J = 8.0 Hz,
1H), 6.17 (s, 2H), 3.94 (s, 3H), 3.88 (s, 9H), 3.83 (s, 3H); 13C
NMR (CDCl3, 100 MHz): δ 159.9, 159.3, 148.9, 148.1, 132.8,
129.8, 119.1, 118.1, 111.1, 108.8, 108.2, 90.8, 55.9, 55.88,
55.81, 55.3; IR (CHCl3) νmax: 3435, 2998, 2932, 2835, 1604,
1577, 1513, 1464, 1418, 1330, 1263, 1231, 1203, 1155, 1117,
1060, 1025 cm−1; ESI-MS m/z: 331.1 [M + H]+.49
4.2.3. (E,Z)-1-(4′-Fluorostyryl)-2,4,6-trimethoxybenzene
(4c). Mixture of cis/trans isomers (17.1:82.8 ratio determined
based on HPLC); brown crystalline solid; mp 70−72 °C; 1H
NMR (CDCl3, 400 MHz) of trans-isomer: δ 7.47 (m, 2H),
7.43−7.39 (d, J = 16.4 Hz, 1H), 7.31−7.27 (d, J = 16.4 Hz,
1H), 7.0 (t, J = 8.8 Hz, 2H), 6.16 (s, 2H), 3.86 (s, 6H), 3.82
(s, 3H); 13C NMR (CDCl3, 100 MHz) of mixture of cis/trans
isomers: δ 163.0 (1JCF = 243.8 Hz), 160.3, 159.4, 158.4, 135.9,
135.8, 129.8, 129.46, 129.38, 128.7, 127.54, 127.46, 120.7,
119.64, 115.3 (2JCF = 21.3 Hz), 114.5 (
2JCF = 21.3 Hz), 108.0,
90.8, 55.8, 55.4, 55.3; 19F NMR (CDCl3, 376.5 MHz): δ
−115.63 (m, 1F), −116.29 (m, 1F); IR (CHCl3) νmax: 3400,
2919, 2850, 1904, 1733, 1605, 1579, 1508, 1455, 1417, 1331,
1223, 1205, 1155, 1118, 1094, 1038, 1019 cm−1; ESI-MS m/z:
289.1 [M + H]+.49
4.2.4. (E)-1-(3′-Chlorostyryl)-2,4,6-trimethoxybenzene
(4d). Trans-isomer (98.6% determined based on HPLC);
white crystalline solid; mp 81−83 °C; 1H NMR (CDCl3, 400
MHz): δ 7.49 (s, 1H), 7.39 (s, 2H), 7.36 (d, J = 7.6 Hz, 1H),
7.23 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.16 (s,
2H), 3.88 (s, 6H), 3.84 (s, 3H); 13C NMR (CDCl3, 100
MHz): δ 160.6, 159.7, 141.7, 134.4, 129.6, 128.3, 126.3, 125.9,
124.4, 121.3, 107.7, 90.8, 55.8, 55.3; IR (CHCl3) νmax: 3000,
2937, 2837, 1605, 1587, 1491, 1468, 1455, 1410, 1330, 1212,
1156, 1120, 1061, 1038 cm−1; ESI-MS m/z: 305.0 [M + H]+.49
4.2.5. (E,Z)-1-(2′-Chlorostyryl)-2,4,6-trimethoxybenzene
(4e). Mixture of cis/trans isomers (5.8:94.1 ratio based on
HPLC); white amorphous solid; mp 94−95 °C; 1H NMR
(CDCl3, 400 MHz) of trans-isomer: δ 7.87 (d, J = 16.4 Hz,
1H), 7.72 (d, J = 8.0 Hz, 1H), 7.38 (m, 2H), 7.25 (t, J = 7.6
Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 6.16 (s, 2H), 3.88 (s, 6H),
3.84 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ 160.6, 159.7,
137.8, 133.0, 129.5, 127.4, 126.7, 126.1, 125.8, 122.2, 108.1,
Figure 11. Analysis of aggregation of α-syn-eGFP fusion protein. (A,B) Maps of the plasmids used for integration of the α-syn-eGFP gene
expression cassettes into the yeast strain BC300. The red arrows indicate the restriction sites that were used for linearizing the plasmids for
integration. (C) Fluorescence pictures of cells expressing two copies of α-syn-eGFP fusion protein in the absence of compounds. (D) Fluorescence
pictures of cells expressing two copies of α-syn-eGFP fusion protein in the presence of compound 4s (5 μM concentration).
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90.8, 55.8, 55.3; IR (CHCl3) νmax: 3785, 2923, 2850, 1737,
1604, 1585, 1491, 1468, 1437, 1416, 1384, 1330, 1214, 1205,
1191, 1155, 1119, 1060, 1033 cm−1; ESI-MS: 305.0 [M +
H]+.49
4.2.6. (E)-1-(2′-Bromostyryl)-2,4,6-trimethoxybenzene
(4f). Trans-isomer (98.2% determined based on HPLC);
white crystalline solid; mp 109−111 °C; 1H NMR (CDCl3,
400 MHz): δ 7.84 (d, J = 16.8 Hz, 1H), 7.71 (d, J = 7.6 Hz,
1H), 7.55 (d, J = 8.0 Hz, 1H), 7.35−7.26 (m, 2H), 7.06 (m,
1H), 6.18 (s, 2H), 3.90 (s, 6H), 3.85 (s, 3H); 13C NMR
(CDCl3, 100 MHz): δ 160.6, 159.7, 139.4, 132.8, 128.5, 127.7,
127.4, 126.3, 123.9, 122.3, 107.9, 90.7, 55.8, 55.3; IR (CHCl3)
νmax: 3400, 3058, 3000, 2959, 2935, 2837, 2532, 1956, 1822,
1742, 1604, 1582, 1491, 1467, 1435, 1416, 1346, 1330, 1277,
1258, 1191, 1177, 1156, 1120, 1061, 1038, 1021 cm−1; ESI-MS
m/z: 350.8 [M + H]+.49
4.2.7. (E)-1-(4′-Bromostyryl)-2,4,6-trimethoxybenzene
(4g). Trans-isomer (96.9% determined based on HPLC);
brown crystalline solid; mp 95−96 °C; 1H NMR (CDCl3, 400
MHz): δ 7.41−7.33 (m, 6H), 6.13 (s, 2H), 3.84 (s, 6H), 3.80
(s, 3H); 13C NMR (CDCl3, 100 MHz): δ 160.7, 159.6, 138.7,
131.4, 128.4, 127.6, 120.6, 120.0, 107.8, 90.8, 55.7, 55.3; IR
(CHCl3) νmax: 3368, 3000, 2924, 2850, 1740, 1602, 1580,
1492, 1466, 1455, 1435, 1330, 1214, 1205, 1189, 1175, 1156,
1120, 1062, 1038, 1006 cm−1; ESI-MS m/z: 350.8 [M + H]+.49
4.2.8. (E)-1-(4′-Chlorostyryl)-2,4,6-trimethoxybenzene
(4h). Trans-isomer (96.4% determined based on HPLC);
white crystalline solid; mp 98−100 °C; 1H NMR (CDCl3, 400
MHz): δ 7.43 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 4.4 Hz, 2H),
7.27 (d, J = 8.8 Hz, 2H), 6.16 (s, 2H), 3.87 (s, 6H), 3.83 (s,
3H); 13C NMR (CDCl3, 100 MHz): δ 160.4, 159.6, 138.2,
131.9, 128.5, 128.4, 127.3, 120.5, 107.8, 90.8, 55.7, 55.3; IR
(CHCl3) νmax: 3400, 2922, 2851, 1741, 1603, 1581, 1494,
1385, 1331, 1205, 1118, 1156, 1020 cm−1; ESI-MS m/z: 305.0
[M + H]+.49
4.2.9. (E)-1-(2′-Iodostyryl)-2,4,6-trimethoxybenzene (4i).
Trans-isomer (99.2% determined based on HPLC); white
crystalline solid; mp 121−122 °C; 1H NMR (CDCl3, 400
MHz): δ 7.83 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 16.5 Hz, 1H),
7.67 (d, J = 8.0 Hz, 1H), 7.32 (m, 2H), 6.88 (t, J = 7.5 Hz,
1H), 6.16 (s, 2H), 3.89 (s, 6H), 3.83 (s, 3H); 13C NMR
(CDCl3, 100 MHz): δ 160.6, 159.7, 142.5, 139.4, 133.5, 128.8,
128.0, 125.7, 122.4, 107.8, 100.7, 90.7, 55.9, 55.4; IR (CHCl3)
νmax: 3436, 2921, 2850, 1603, 1578, 1457, 1432, 1416, 1384,
1330, 1216, 1155, 1119, 1020 cm−1; ESI-MS m/z: 396.9 [M +
H]+.49
4.2.10. (E/Z)-1-(4′-Methylstyryl)-2,4,6-trimethoxy-benzene
(4j). Mixture of cis/trans isomers (6.4:88.8 ratio determined
based on HPLC); brown crystalline solid; mp 90−92 °C; 1H
NMR (CDCl3, 400 MHz) of trans-isomer: δ 7.45−7.31 (m,
4H), 7.13 (d, J = 8.0 Hz, 2H), 6.16 (s, 2H), 3.87 (s, 6H), 3.83
(s, 3H), 2.33 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ 159.3,
158.7, 136.2, 135.6, 129.2, 128.5, 125.4, 118.1, 107.6, 90.1,
55.1, 54.7, 20.6; IR (CHCl3) νmax: 3785, 3436, 2923, 2850,
1604, 1585, 1491, 1437, 1416, 1384, 1330, 1214, 1205, 1191,
1155, 1119, 1060, 1033 cm−1; ESI-MS m/z: 285.1 [M + H]+.49
4.2.11. (E)-1-(2′,4′-Dichlorostyryl)-2,4,6-trimethoxyben-
zene (4k). Trans-isomer (99.2% determined based on
HPLC); white crystalline solid; mp 129−131 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.79 (d, J = 16.4 Hz, 1H), 7.64 (d, J =
8.8 Hz, 1H), 7.36 (m, 2H), 7.20 (d, J = 8.4 Hz, 1H), 6.15 (s,
2H), 3.88 (s, 6H), 3.83 (s, 3H); 13C NMR (CDCl3, 100
MHz): δ 160.8, 159.7, 136.4, 133.3, 132.0, 129.2, 127.0, 126.8,
124.6, 122.7, 107.7, 90.7, 55.8, 55.3; IR (CHCl3) νmax: 3435,
2922, 2851, 1743, 1603, 1579, 1513, 1466, 1414, 1384, 1327,
1249, 1215, 1204, 1156, 1118, 1099, 1019 cm−1; ESI-MS m/z:
339.0 [M + H]+.49
4.2.12. (E)-1-(3′-Bromo-4′-fluorostyryl)-2,4,6-trimethoxy-
benzene (4l). Trans-isomer (90% determined based on
HPLC); white amorphous solid; mp 110−112 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.67 (d, J = 7.0 Hz, 1H), 7.39−7.25 (m,
3H), 7.07 (t, J = 8.5 Hz, 1H), 6.16 (s, 2H), 3.88 (s, 6H), 3.84
(s, 3H); 13C NMR (CDCl3, 100 MHz): δ 159.7, 158.7, 157.8
(d, 1JCF = 244 Hz), 136.7, 129.7, 126.3, 125.6, 120.0, 115.5 (d,
2JCF = 22.2 Hz), 108.2 (d,
2JCF = 21 Hz), 106.6, 89.8, 54.9,
54.5; 19F NMR (CDCl3, 376.5 Hz): δ −111.06 (m, 1F); IR
(CHCl3) νmax: 3436, 3003, 2923, 2838, 1726, 1608, 1581,
1496, 1469, 1455, 1436, 1420, 1344, 1260, 1247, 1216, 1202,
1192, 1158, 1118, 1061, 1039 cm−1; ESI-MS m/z: 366.9 [M +
H]+.49
4.2.13. (E)-1-(4′-(tert-Butyl)styryl)-2,4,6-trimethoxyben-
zene (4m). Trans-isomer (99.7% determined based on
HPLC); white crystalline solid; mp 83−84 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.45 (t, J = 8.4 Hz, 3H), 7.35 (m, 3H),
6.16 (s, 2H), 3.86 (s, 6H), 3.83 (s, 3H), 1.32 (s, 9H); 13C
NMR (CDCl3, 100 MHz): δ 160.0, 159.4, 149.5, 136.9, 129.8,
125.8, 125.3, 119.2, 108.3, 90.8, 55.8, 55.3, 34.5, 31.3; IR
(CHCl3) νmax: 2960, 1837, 1729, 1601, 1581, 1514, 1465,
1416, 1363, 1330, 1270, 1217, 1204, 1155, 1116, 1061, 1039
cm−1; ESI-MS m/z: 327.1 [M + H]+.49
4.2.14. (E)-1-(3′,5′-Dimethylstyryl)-2,4,6-trimethoxyben-
zene (4n). Trans-isomer (98.3% determined based on
HPLC); white crystalline solid; mp 145−147 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.42−7.31 (dd, J = 12.4, 16.8 Hz, 2H),
7.13 (s, 2H), 6.83 (s, 1H), 6.16 (s, 2H), 3.87 (s, 6H), 3.83 (s,
3H), 2.32 (s, 6H); 13C NMR (CDCl3, 100 MHz): δ 160.1,
159.5, 139.5, 137.7, 130.3, 128.3, 124.1, 119.4, 108.4, 90.9,
55.8, 55.3, 21.3; IR (CHCl3) νmax: 3001, 2920, 2850, 1737,
1603, 1580, 1490, 1457, 1411, 1329, 1222, 1200, 1156, 1113,
1063, 1031 cm−1; ESI-MS m/z: 299.1 [M + H]+.49
4.2.15. (E)-1-(2′-Methylstyryl)-2,4,6-trimethoxy-benzene
(4o). Trans-isomer (95.4% determined based on HPLC);
white crystalline solid; mp 96−98 °C; 1H NMR (CDCl3, 400
MHz): δ 7.68 (m, 2H), 7.26−7.09 (m, 4H), 6.17 (s, 2H), 3.87
(s, 6H), 3.83 (s, 3H), 2.38 (s, 3H); 13C NMR (CDCl3, 100
MHz): δ 160.1, 159.4, 138.7, 135.3, 130.1, 128.1, 126.5, 126.0,
124.9, 120.7, 108.5, 90.8, 55.8, 55.3, 20.0; IR (CHCl3) νmax:
3000, 2937, 2837, 1605, 1587, 1491, 168, 1455, 1418, 1330,
1212, 1191, 1156, 1120, 1061, 1038 cm−1; ESI-MS m/z: 285.1
[M + H]+.49
4.2.16. (E)-1-(4′-Iodostyryl)-2,4,6-trimethoxybenzene (4p).
Trans-isomer (95.1% determined based on HPLC); brown
crystalline solid; mp 91−92 °C; 1H NMR (CDCl3, 400 MHz):
δ 7.63 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 3.2 Hz, 2H), 7.24 (d, J
= 8.4 Hz, 2H), 6.16 (s, 2H), 3.88 (s, 6H), 3.84 (s, 3H); 13C
NMR (CDCl3, 100 MHz): δ 160.4, 159.6, 139.2, 137.4, 128.5,
127.9, 120.6, 107.6, 91.3, 90.7, 55.7, 55.3; IR (CHCl3) νmax:
3435, 2924, 2851, 1744, 1603, 1578, 1455, 1416, 1204, 1155,
1121, 1059, 1017, 1002 cm−1; ESI-MS m/z: 396.9 [M + H]+.49
4.2.17. (E,Z)-1-(3′,4′-Difluorostyryl)-2,4,6-trimethoxyben-
zene (4q). Mixture of cis/trans isomers (6.8:93.1 ratio
determined based on HPLC); white crystalline solid; mp
79−80 °C; 1H NMR (CDCl3, 400 MHz) of trans-isomer: δ
7.34−7.25 (m, 3H), 7.15 (m, 1H), 7.10−7.04 (m, 1H), 6.16
(s, 2H), 3.88 (s, 6H), 3.83 (s, 3H); 13C NMR (CDCl3, 125
MHz): δ 160.5, 159.5, 151.5 (1JCF = 176 Hz), 150.1 (
1JCF =
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176 Hz), 137.1, 127.5, 122.2, 120.9, 117.0 (d, 2JCF = 17.1 Hz),
114.1 (d, 2JCF = 17.2 Hz), 107.4, 90.7, 55.7, 55.3;
19F NMR
(CDCl3, 376.5 Hz): δ −138.73 (m, 1F), −141.08 (m, 1F); IR
(CHCl3) νmax: 3008, 2939, 2840, 2153, 1581, 1514, 1463,
1432, 1414, 1349, 1323, 1293,1201, 1271, 1223, 1150,
1120,1061, 1037 cm−1; ESI-MS m/z: 307.1 [M + H]+.49
4.2.18. (E,Z)-1-(3′,4′-Dichlorostyryl)-2,4,6-trimethoxyben-
zene (4r). Mixture of cis/trans isomers (10.6:89.3 ratio
determined based on HPLC); white amorphous solid; mp
104−105 °C; 1H NMR (CDCl3, 400 MHz) of trans-isomer: δ
7.56 (d, J = 2.0 Hz, 1H), 7.37−7.29 (m, 4H), 6.16 (s, 2H),
3.88 (s, 6H), 3.84 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ
160.7, 159.7, 140.0, 132.3, 130.2, 129.6, 127.6, 127.0, 125.3,
121.7, 107.3, 90.6, 55.7, 55.3; IR (CHCl3) νmax: 3436, 3003,
2936, 2839, 2483, 1898, 1605, 1587, 1577, 1507, 1469, 1457,
1437, 1420, 1384, 1331, 1258, 1219, 1204, 1188, 1156, 1121,
1062, 1039, 1016 cm−1; ESI-MS m/z: 339.0 [M + H]+.49
4.2.19. (E)-2-(4-Methoxystyryl)-1,3,5-trimethoxybenzene
(4s). White solid; mp 61−64 °C; 1H NMR (CDCl3, 400
MHz) of trans-isomer: 7.45−7.43 (m, 3H), 7.26−7.23 (m,
2H), 6.87 (d, J = 8.4 Hz, 2H), 6.16 (s, 2H), 3.87 (s, 3H), 3.83
(s, 3H), 3.75 (s, 3H); 13C NMR (CDCl3, 100 MHz): 160.23,
159.34, 158.37, 158.12, 132.55, 130.21, 129.51, 129.31, 127.30,
117.93, 114.23, 113.98, 113.06, 108.30, 90.82, 55.76, 55.55,
55.29, 55.28; IR (CHCl3) νmax: 3437, 2912, 2847, 2312, 1724,
1600, 1501, 1422, 1300, 1265, 1112, 1013 cm−1; ESI-MS
(−ve) m/z: 299.0 [M − H]−.50
4.2.20. (E)-5-(2,4,6-Trimethoxystyryl)benzo[d][1,3]dioxole
(4t). Off-white solid; Mixture of cis/trans isomers (28:72 based
on 1H NMR); 1H NMR (CDCl3, 400 MHz) of trans isomer:
7.32 (m, 1H), 7.22 (m, 1H), 7.17 (s, 1H), 6.92 (d, J = 8 Hz,
1H), 6.77 (d, J = 8 Hz, 1H), 6.31 (s, 2H), 6.12 (s, 2H); 3.87
(s, 6H), 3.83 (s, 3H); IR (CHCl3) νmax: 3435, 3002, 2938,
2638, 1919, 1725, 1601, 1516, 1490, 1468, 1457, 1437, 1419,
1270, 1217, 1206, 1193, 1184, 1156, 1119, 1108, 1065, 1038,
1014; ESI-MS m/z: 316.0 [M + H]+.49
4.2.21. ((E)-2-(2,4-Bis(trifluoromethyl)styryl)-1,3,5-trime-
thoxybenzene (4u). Mixture of cis/trans isomers (5:95 ratio
based on HPLC); white solid; 1H NMR (CDCl3, 400 MHz) of
trans-isomer: δ 7.95−7.85 (m, 3H), 7.72 (d, J = 8.4 Hz, 1H),
7.50 (d, J = 16.0 Hz, 1H), 6.17 (s, 2H), 3.89 (s, 6H), 3.85 (s,
3H); IR (CHCl3) νmax: 3435, 2926, 2849, 2318, 1726, 1603,
1503, 1458, 1417, 1343, 1305, 1277, 1224, 1207, 1124, 1082,
1053, 1016 cm−1; ESI-MS m/z: 407.0 [M + H]+.49
4.2.22. (E)-Ethyl 4-(2,4,6-Trimethoxystyryl)benzoate (4v).
Mixture of cis/trans isomers (10:90 based on 1H NMR);
brown solid; 1H NMR (CDCl3, 400 MHz) of trans-isomer: δ
8.02−7.97 (m, 2H), 7.58−7.50 (m, 4H), 6.17 (s, 2H), 4.38 (q,
J = 2.8, 4.0 Hz, 2H), 3.89 (s, 6H), 3.85 (s, 3H), 1.40 (t, J = 2.8
Hz); 13C NMR (CDCl3, 100 MHz) 166.75, 160.23, 159.23,
158.34, 144.38, 129.93, 129.80, 128.34, 128.94, 128.58, 125.85,
122.45, 107.67, 90.72, 60.75, 55.79, 55.38, 55.38, 14.40; IR
(CHCl3) νmax: 3401, 2938, 2840, 1605, 1507, 1456, 1419,
1331, 1257, 1218, 1203, 1156, 1121, 1062, 1039, 1016 cm−1;
ESI-MS m/z: 343.2 [M + H]+.49
4.2.23. (Z)-1-(3′,5′-Di(trifluoromethyl)styryl)-2,4,6-trime-
thoxybenzene (4w). Brown crystalline solid; 1H NMR
(CDCl3, 400 MHz): δ 7.87 (s, 2H), 7.65 (s, 1H), 7.54 (d, J
= 13.2 Hz, 1H), 7.50 (d, J = 13.2 Hz, 2H), 6.18 (s, 2H), 3.91
(s, 6H), 3.86 (s, 3H); 13C NMR (CDCl3, 125 MHz): δ 161.2,
159.9, 141.9, 131.5 (q, 1JC−F = 27.7 Hz), 126.4, 125.7, 124.6,
123.5, 122.5, 119.5 (t, 2JC−F = 3.0 Hz), 106.9, 90.6, 55.8, 55.4;
IR (CHCl3) νmax: 3432, 3073, 3052, 2893, 2923, 2853, 1732,
1600, 1503, 1412, 1323, 1112 cm−1; ESI-MS m/z: 407.0 [M +
H]+.49
4.2.24. (E,Z)-2-(2,4,6-Trimethoxystyryl)naphthalene (4x).
Mixture of cis/trans isomers (33:67 ratio determined based on
HPLC); white amorphous solid; mp 93−94 °C; 1H NMR
(CDCl3, 400 MHz): δ 7.81 (m, 6H), 7.72 (m, 2H), 7.61 (s,
1H), 7.55 (m, 2H), 7.44−7.36 (m, 4H), 7.31 (d, J = 8.8 Hz,
1H), 6.82 (d, J = 12.0 Hz, 1H), 6.51 (d, J = 12.4 Hz, 1H), 6.19
(s, 2H), 6.12 (s, 2H), 3.91 (s, 6H), 3.84 (s, 6H), 3.53 (s, 6H);
13C NMR (CDCl3, 125 MHz): δ 160.9, 160.2, 159.5, 158.4,
137.2, 136.8, 133.8, 133.2, 132.6, 132.4, 130.9, 129.8, 128.0,
127.9, 127.8, 127.6, 127.4, 127.0, 126.7, 126.0, 125.9, 125.7,
125.6, 125.4, 125.2, 123.7, 121.3, 120.2, 108.0, 90.7, 90.5, 55.8,
55.4, 55.3, 53.4; IR (CHCl3) νmax: 3436, 2923, 2849, 1737,
1603, 1455, 1415, 1330, 1224, 1204, 1156, 1060, 1038 cm−1;
ESI-MS m/z: 321.1 [M + H]+.49
4.2.25. (E,Z)-1-Styryl-2,4,5-trimethoxybenzene (4y). Mix-
ture of cis/trans isomers (20:80 ratio, determined by 1H
NMR); light yellow oil; 1H NMR (CDCl3, 400 MHz) of
mixture of cis/trans-isomer: δ 7.52 (d, J = 7.6 Hz, 1H), 7.46
(d, J = 16.4 Hz, 1H), 7.35 (m, 2H), 7.28 (m, 2H), 7.21 (m,
3H), 7.16 (m, 3H), 6.99 (d, J = 16.4 Hz, 1H), 6.70 (m, 2H),
6.55 (m, 3H), 3.91 (s, 12H), 3.81 (s, 3H), 3.44 (s, 3H); 13C
NMR (CDCl3, 100 MHz): δ 151.8, 149.6, 149.1, 143.5, 142.4,
138.1, 137.7, 128.8, 128.6, 128.1, 127.0, 126.8, 126.3, 125.0,
123.0, 118.3, 117.4, 113.3, 109.5, 97.8, 97.3, 56.7, 56.6, 56.1,
56.0, 55.9; IR (CHCl3) νmax: 3436, 3077, 3053, 2999, 2935,
2832, 1734, 1608, 1583, 1512, 1491, 1465, 1410, 1328, 1163,
1110 cm−1; ESI-MS m/z: 271.1 [M + H]+.49
4.2.26. (E,Z)-1-Styryl-2,4-dimethoxybenzene (4z). Mixture
of cis/trans isomers (73:25 ratio, determined based on
HPLC), light yellow oil; 1H NMR (CDCl3, 400 MHz): δ
7.50 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 16.4 Hz, 1H), 7.32−7.03
(m, 10H), 7.01 (d, J = 16.4 Hz, 1H), 6.63 (d, J = 12.4 Hz, 1H),
6.54−6.43 (m, 4H), 6.28 (d, 8.4 Hz, 1H), 3.82 (s, 3H), 3.79
(s, 3H), 3.76 (s, 3H), 3.74 (s, 3H); 13C NMR (CDCl3, 100
MHz): δ 160.6, 160.4, 158.3, 158.1, 138.3, 137.7, 130.6, 129.0,
128.8, 128.6, 128.1, 127.2, 127.0, 126.7, 126.3, 125.4, 123.3,
119.5, 118.8, 105.0, 104.2, 98.5, 98.3, 55.55, 55.50, 55.44,
55.34; IR (CHCl3) νmax: 3053, 3003, 2957, 2936, 2835, 2592,
1950, 1882, 1608, 1576, 1503, 1490, 1463, 1438, 1417, 1288,
1208, 1183, 1159, 1118, 1107, 1072 cm−1; ESI-MS m/z: 241.1
[M + H]+.49
4.2.27. (E,Z)-1-Styryl-2-methoxybenzene (4aa). Mixture of
cis/trans isomers (92.2:7.8 ratio, determined based on HPLC),
colourless oil; 1H NMR (CDCl3, 400 MHz) of cis-isomer
(92%): δ 7.23−7.12 (m, 7H), 6.89 (d, J = 8.0 Hz, 1H), 6.76−
6.60 (m, 3H), 3.81 (s, 3H); 13C NMR (CDCl3, 100 MHz): δ
157.2, 137.3, 130.2, 130.1, 128.8, 128.6, 128.0, 126.9, 126.2,
125.8, 120.2, 110.7, 55.4; IR (CHCl3) νmax: 3436, 2938, 2850,
1590, 1513, 1462, 1446, 1418, 1311, 1259, 1224, 1153, 1138,
1025 cm−1; ESI-MS m/z: 211.1 [M + H]+.49
4.2.28. (E)-1-Styryl-3,4-dimethoxybenzene (4ab). Trans-
isomer (100% determined based on HPLC); white amorphous
solid; mp 121−122 °C; 1H NMR (DMSO-d6, 400 MHz): δ
7.44 (d, J = 7.2 Hz, 2H), 7.30 (t, J = 7.2 Hz, 2H), 7.20 (d, J =
7.2 Hz, 1H), 7.01−6.89 (m, 4H), 6.74 (d, J = 8.4 Hz, 1H),
3.84 (s, 3H), 3.77 (s, 3H); 13C NMR (DMSO-d6, 100 MHz):
δ 149.2, 149.0, 137.6, 130.5, 128.7, 128.5, 127.3, 126.8, 126.4,
120.0, 111.3, 109.0, 55.9, 55.8; IR (CHCl3) νmax: 3436, 2938,
2839, 1590, 1513, 1462, 1446, 1418, 1311, 1259, 1224, 1154,
1138, 1025 cm−1; ESI-MS m/z: 241.1 [M + H]+.49
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4.2.29. (E,Z)-1-Styryl-4-methoxybenzene (4ac). Mixture of
cis/trans isomers (1.3:98.6 ratio determined based on HPLC);
white amorphous solid; mp 106−108 °C; 1H NMR (CDCl3,
400 MHz) of cis/trans isomers: δ 7.49 (dd, J = 7.2, 8.8 Hz,
3H), 7.34 (t, J = 7.6 Hz, 2H), 7.28−7.16 (m, 9H), 7.08−6.95
(m, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H),
6.51 (d, J = 1.6 Hz, 2H), 3.82 (s, 3H), 3.77 (s, 3H); 13C NMR
(CDCl3, 100 MHz): δ 159.3, 158.6, 137.6, 130.1, 129.7, 129.6,
128.8, 128.7, 128.69, 128.67, 128.25, 128.22, 127.7, 127.2,
126.9, 126.6, 126.5, 126.2, 114.1, 113.5, 55.3, 55.2; IR
(CHCl3) νmax: 3745, 3436, 3078, 3053, 3021, 2961, 2934,
2836, 1605, 1510, 1463, 1446, 1421, 1297, 1252, 1179, 1150,
1112, 1072 cm−1; ESI-MS m/z: 211.1 [M + H]+.49
4.3. Cloning of α-Syn, Bax, and βA4 Genes in Yeast
Integrating Vectors. The gene coding for human α-syn, its
A53T mutant, Bax, and βA4 was cloned using standard
molecular biology techniques as either BglII-XbaI or BamHI-
XbaI fragments in appropriate yeast integration vectors. The
maps of the resultant plasmids have been shown either in the
manuscript or in the Supporting Information.
4.4. Construction of Yeast Strains That Bear
Integrated Copies of the α-Syn, Bax, and βA4 Genes.
The integrative plasmids, obtained after cloning of the human
genes, were linearized with appropriate restriction enzymes,
before transformation into the yeast strain W303-1a (Mata,
ade2, his3, leu2, trp1, ura3; ATCC 208352). It has been
referred to here as the strain, BC300. Integration of plasmids
into the yeast genome at specific chromosomal sites of BC300
occurred via homologous recombination.14
4.5. Growth of Recombinant Yeast Cells in Liquid and
Solid-Agar Media. The recombinant cells were grown either
in synthetic dextrose minimal medium (SD; contained 0.67%
bacto-yeast nitrogen base, with no supplements, and 2%
glucose which is also known as dextrose) or in synthetic
galactose minimal medium (SG; contained 0.67% bacto-yeast
nitrogen base, with no supplements, and 2% galactose). SD
and SG media are selected for the presence of the
chromosomally integrated plasmid. The solid agar SD, SG,
and YPD plates contained the same ingredients plus 2% agar.
For growing pre-cultures of cells, complete YPD medium,
containing 2% bacto-peptone and 1% yeast extract, was used.51
4.6. Microtiter Plate Assays for Identifying Com-
pounds That Rescue Yeast Cells from the Toxicity of α-
Syn, Bax, and βA4. α-syn, Bax, or βA4-expressing yeast cells
were initially grown in SD medium at 30 °C, for 24 h. Cells
were harvested, washed with sterile water, and then
resuspended in SG medium. Cells (103) were inoculated in
195 μL SG medium (that contained 2% galactose and 0.2%
glucose, with appropriate nutrients); for the initial screen, 5 μL
of individual compounds in the methoxy-stilbene chemical
library was added to cell suspension such that the final
concentration of compounds was 10 μM and a DMSO
concentration <0.5%. Control cells (containing no α-syn, Bax
or βA4), in the absence of compounds but with a DMSO
concentration <0.5%, were grown in SG in the same manner.
The two flavonoids, fisetin and quercetin, which have been
identified as compounds with the therapeutic potential in a
yeast-based model of α-synucleopathy, were used as positive
controls.52 Unfortunately, resveratrol (1) and piceatannol (2)
(Figure 1A) did not restore cell growth blocked by two copies
of α-syn; rescue of α-syn’s toxicity in yeast by resveratrol (1)
and piceatannol (2) has not been reported in the literature.
Cell growth was determined via measurement of optical
density at the wavelength of 600 nm (OD600). The OD600 was
measured, before the plates were shaken, using a Synergy HT
BioTek plate reader, and the parameters were set using the
KC4 software. The OD600 was measured once again after 48
and 72 h of shaking at 30 °C on a rotating platform set at 200
rpm. The growth of each set of cells incubated with different
compounds is calculated by subtraction of the OD600 at 72 h
from the initial OD600 at 0 h and is then expressed as a
percentage growth compared to the control cells (that
contained just DMSO and no compound) using Excel.
Compounds showing a repetitive high percentage cell growth
of 20% and over in the following yeast strains were identified:
two-copy α-syn, three-copy α-syn, three-copy mutant A53T α-
syn strains, and Bax. The identified compounds were then
further tested in the two-copy βA4-expressing yeast cells.
4.7. Detection of Dead Cells with Phloxine B Dye. Cell
death was measured by staining with Phloxine B which is a
fluorescent dye. Live (i.e., viable) cells expel Phloxine B dye;
the dye accumulates only in dead cells. This can be observed
using a fluorescent microscope. Phloxine B (Sigma, P-4030-
25G) was added to both test yeast cells (bearing the human
gene) and control yeast cells (that contain empty plasmid) to a
final concentration of 5 μg/m. After incubation at 30 °C for 30
min in the dark, the cells were washed with sterile phosphate-
buffered saline (PBS) three times. Cells were then mounted on
a hemocytometer for cell counting and on a glass slide for
microscopic examination with an Olympus BX-51 fluorescent
microscope (at excitation/emission 570/650 nm). Image
capturing was done using a Leica digital imaging color camera.
4.8. Yeast Colony Formation. The method was used to
distinguish between the numbers of live cells in control cells
and cells expressing α-syn, Bax, or βA4 in the presence and
absence of “hit” compounds. Yeast strains of interest were
grown in10 mL of YPD liquid medium as pre-cultures. Cells
were centrifuged, washed twice with SG, and resuspended in a
final volume of 10 mL. The OD600 was determined, and the
cells were also counted using a hemocytometer. Three
hundred cells were spread on a fresh SG agar plate (with
appropriate amino acids), containing 10, 5, and 2.5 μM
concentration of a compound of interest. Control cells
contained no compound. The plates were incubated at 30
°C for 3−4 days. The colonies formed were counted manually,
and the difference in colony numbers from different cultures
was recorded.
4.9. Detection of ROS with Dihydroethidium. An AAT
Bioquest Fluorimetric Intracellular Total ROS Activity Assay
Kit (Catalog #22901) was used to measure ROS. After
expression of protein(s), OD600 was again measured and cells
were counted, and 100 000 cells were pipetted into wells of a
96-well microtiter plate (Corning, # 04815027) in triplicate.
The plate was centrifuged at 800 rpm for 2 min, and
supernatants were discarded. Cells in wells of a microtiter plate
were then resuspended in yeast cell culture medium and
centrifuged for 2 min at 800 rpm. DMSO (40 μL, component
C of the kit) was added to ROS red (component A of the kit)
and mixed well. ROS red is cell-permeable and generates red
fluorescence when it reacts with ROS. The ROS red/DMSO
mixture (20 μL) was added to 10 mL of assay buffer
(component B of the kit) and mixed well. This is regarded as
the working solution. Working solution (100 μL) was added
per well of cells. The plate containing cells was then incubated
for 90 min at 30 °C. Fluorescence was then bottom read with a
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Bio-Tek Synergy HT plate reader at excitation/emission 520/
605 nm.
4.10. Measurement of MMP in Yeast Cells. An AAT
Bioquest JC-10 MMP Assay kit (Catalog #22800) was used for
measuring MMP. The kit uses JC-10 dye and can selectively
enter into the mitochondria. JC-10 changes color from green
to orange as the polarization of the mitochondrial membrane
increases. The reaction is reversible because of the formation
of monomeric (green; emission at 520 nm) and aggregated
(orange or red; emission at 570 nm) forms of JC-10, as MMP
increases. In healthy cells, JC-10 accumulates in the
mitochondrial matrix and forms orange (or red) fluorescent
aggregates, but in necrotic or apoptotic cells, JC-10 disperses
out of the mitochondria and changes to the monomeric form.
Cells are then stained with green fluorescence. After expression
of human proteins in yeast, OD600 was measured and cells were
counted, and 100 000 cells were pipetted in triplicate into wells
of a 96-well microtiter plate (Corning, 04815027). Cells were
centrifuged at 800 rpm for 2 min. Cells were then resuspended
in yeast cell culture medium and centrifuged for 2 min at 800
rpm. All kit components were thawed at room temperature.
Component A (50 μL, 100x JC-10) was added into 5 mL of
assay buffer A (component B) and mixed well (this is the
working solution). The working solution (50 μL) was added to
wells of a microtiter plate, and the plate was incubated for 90
min at 30 °C (in the dark). Assay buffer B (50 μL, component
C) was added to each well already containing cells and JC-10.
The plate was centrifuged for 2 min at 800 rpm before loading
the plate on to the Bio-Tek Synergy HT plate reader so that
excitation/emission 490/525 nm and 540/590 nm could be
read from the bottom. The ratio of aggregated/monomeric JC-
10 was plotted.
4.11. TUNEL Assay to Detect Nuclear DNA Fragmen-
tation of Yeast Cells. An AAT Bioquest TUNEL Apoptosis
Assay kit (Catalog #22844) was used for the detection of DNA
fragmentation. The kit works by incorporating the fluorescence
dye TF3-dUTP at the 3′-OH ends of apoptotic DNA
fragments. After the expression of the protein of interest,
OD600 was measured, and cells were counted, and 30 000 cells
were pipetted on to wells of a 96-well microtiter plate
(Corning, 04815027) in triplicate. The plate was then
centrifuged for 2 min at 800 rpm. Supernatants were removed,
and 100 μL of 4% formaldehyde fixative buffer was added to
each well and incubated for 30 min at room temperature. The
fixative buffer was removed and cells were washed twice with
PBS. Component A (6 μL, 100× TF3-dUTP) was added to
600 μL of component B (reaction buffer). The above-
mentioned mixture (50 μL) was added to wells of a 96-well
microtiter plate and incubated for 120 min. Cells were then
washed and fluorescence was monitored from the bottom with
the help of a Bio-Tek Synergy HT plate reader at excitation/
emission 550/590 nm. An Olympus BX-51 fluorescence
microscope with a Leica digital imaging camera was used to
take the microscopic images.
4.12. Staining with Hoechst Dye for Monitoring Live
Cells. Hoechst 33258 (pentahydrate (bisbenzimide) Fluo-
roPure grade; Cat #H21491; Thermo Fisher Scientific) is a
nucleic acid stain that is widely used to detect live cells. When
bound to double-stranded DNA, the Hoechst dye emits blue
fluorescence. Yeast cells expressing a protein of interest were
counted, and 1 × 106 cells were pipetted into an Eppendorf
tube. Cells were incubated with 5-bromodeoxyuridine for 30
min, and 500 μL of 10 μg/mL of Hoechst 33258 was added to
the tube and incubated for 10 min. Cells were washed with
PBS and viewed under a fluorescence setting using an
Olympus BX-51 fluorescence microscope with a GXCAM-
FLUOMAX fluorescence digital camera, with magnification
60× and Image J software version 1.48.
4.13. DDPH Antioxidation Assay. It is a simple and
quick method for evaluating the antioxidant potential of a
compound, an extract from biological sources. The assay is
based on measuring the decrease in the absorption at 517 nm
of DPPH, whence the compound or extract is mixed with
DPPH solution. DPPH is a stable free radical which changes
color from red to yellow when scavenging. The DPPH
concentration in a sample is reduced when it reacts with
antioxidants, hence the absorbance decreases. The scavenging
potential of the antioxidant is proportional to the degree of
discoloration of DDPH. Initially, 0.1 mM DPPH (Sigma,
D9132) solution was prepared in methanol. For dilution of
DPPH, a PBS/methanol solution (20% PBS, 80% methanol)
was used. The testing was done in 96-well microtiter plates, in
triplicates. Each microtiter plate is setup so that final volume in
each well is 300 μL. Each well has 3 components (volumes in
μL): PBS-methanol (75)/DPPH stock (150)/Compound
stocks(75), and they are added in that order, in triplicate.
4.14. ABTS Antioxidation Assay. ABTS free-radical
scavenging assay was used to determine the total antioxidant
activity of compounds of interest. It is based on the
measurement of ABTS radical cation formation in the presence
of an unknown compound. Trolox [6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid], a water-soluble vitamin
E analog, served as a positive control for inhibiting the
formation of the radical cation. The ABTS-solution, 7 mM
ABTS, 2.45 mM potassium peroxodisulfate in PBS (pH 7.4),
was freshly made and stored in the dark at room temperature
for 4 h to stabilize. The ABTS solution was diluted 1:50 in PBS
to provide an absorbance of ∼0.7 when read at 734 nm. In a
96-well microtiter plate, 20 μL of compounds (from 200 μM
stock solutions) was pipetted in triplicate. For the positive
control, 20 μL of 200 μM Trolox was used. For the negative
control, 20 μL of 10% DMSO was used, and 180 μL of diluted
ABTS solution was added to all wells. The absorbance was
read at 734 nM, in 30 s intervals, over 60 min. The results were
analyzed using Excel.
4.15. Statistical Analyses. Data from experiments were
analyzed by Microsoft Excel 2010 or GraphPad Prism.
Student’s t tests were performed to compare EC50 values
using Excel.
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